Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the advance study

Diabetes

Volumn 63, Issue 3, 2014, Pages 1115-1123

  Lowe, Gordon ^a   Woodward, Mark ^b   Hillis, Graham ^b   Rumley, Ann ^a   Li, Qiang ^b   Harrap, Stephen ^c   Marre, Michel ^d   Hamet, Pavel ^e   Patel, Anushka ^b   Poulter, Neil ^f   Chalmers, John ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d BICHAT HOSPITAL   (France)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FIBRINOGEN; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84894456906     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1625     Document Type: Article

References (32)

1. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841
2. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
3. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126
5. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-1482
6. Danesh J, Lewington S, Thompson SG, et al.; Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-1809
7. Kaptoge S, Di Angelantonio E, Lowe G, et al.; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-140
8. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004;27:889-894
9. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2006;29:329-333
10. Bruno G, Fornengo P, Novelli G, et al. C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes 2009;58:926-933
11. Bruno G, Merletti F, Biggeri A, et al.; Casale Monferrato Study. Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 2005;48:427-434
12. Lowe GDO, Welsh P, Rumley A, Sattar N. Inflammatory cytokines and cardiovascular risk. In Cytokines. Preedy VR, Hunter JR, Eds. St. Helier, U.K., Science Publishers, 2011, p. 235-250
13. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78
14. Sarwar N, Butterworth AS, Freitag DF, et al.; IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012;379:1205-1213
15. Allen TL, Febbraio MA. IL6 as a mediator of insulin resistance: fat or fiction? Diabetologia 2010;53:399-402
16. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-978
17. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GDO. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999;104:246-257
18. Herder C, Schöttker B, Rothenbacher D, et al. Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: results from the ESTHER study. Atherosclerosis 2011;216:244-247
19. Schöttker B, Herder C, Rothenbacher D, et al. Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. Diabetes Care 2013;36:1703-1711
20. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia 2001;44:1118-1120
21. Woodward M. Epidemiology: Study Design and Data Analysis. 2nd ed. Boca Raton, FL, Chapman and Hall/CRC Press, 2005
22. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-2546
23. Newson RB. Comparing the predictive power of survival models using Harrell's C or Somers' D. Stata J 2011;10:339-358
24. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med 2011;30:22-38
25. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21
26. Kaptoge S, Di Angelantonio E, Pennells L, et al.; Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367:1310-1320
27. Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD. Fibrinogen and future cardiovascular disease in people with diabetes: aetiological associations and risk prediction using individual participant data from nine community-based prospective cohort studies. Diab Vasc Dis Res 2013;10: 143-151
28. Deloukas P, Kanoni S, Willenborg C, et al.; The CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new-risk loci for coronary artery disease. Nat Genet 2013;45:25-33
29. Palmer CN, Kimber CH, Doney ASF, et al. Combined effect of inflammatory gene polymorphisms and the risk of ischemic stroke in a prospective cohort of subjects with type 2 diabetes: a Go-DARTS study. Diabetes 2010; 59:2945-2948
30. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005;48:370-378
31. Tong PC, Lee K-F, So W-Y, et al. White blood cell count is associated with macro-and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 2004;27:216-222
32. Chalmers J, Arima H. Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE. J Cardiovasc Pharmacol 2010;55:340-347